Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease

Drugs

Volumn 61, Issue 5, 2001, Pages 685-712

  Dunn, Christopher J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ERGOCALCIFEROL; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; PLACEBO; RISEDRONIC ACID;

ABDOMINAL PAIN; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HIP FRACTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; VERTEBRA FRACTURE;

EID: 0035021131     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161050-00013     Document Type: Review

References (96)

1. 1. Watson JE, editor. Medical-surgical nursing and related physiology. 2nd ed. Eastbourne: W.B. Saunders, 1979
2. 2. Golden BD. The prevention and treatment of osteoporosis. Arthritis Care Res 1998; 11 (2): 124-34
3. 3. Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999 Oct; 15: 285-96
4. 4. Johansen A, Stone M, Rawlinson F. Bisphosphonates and the treatment of bone disease in the elderly. Drugs Aging 1996 Feb; 8: 113-26
5. 5. Ali SY, Sajdera SW, Anderson HC. Isolation and characterization of calcifying matrix vesicles from epiphyseal cartilage. Proc Natl Acad Sci U S A 1970; 67: 1513-20
6. 6. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1261-4
7. 7. Reynolds JJ, Morgan DB. A combined in vivo and in vitro study of the effects of diphosphonates on bone resorption. J Bone Joint Surg Br 1970; 52B: 796
8. 8. Strates BS, Firschein HE, Urist MR. Alkaline phosphatase and failure of calcification under the influence of a diphosphonate. Biochim Biophys Acta 1971; 244: 121-4
9. 9. Dunn CJ, Fitton A, Sorkin EM. Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 1994; 5 (6): 446-74
10. 10. Kylstra JW, Bekker PJ, Axelrod DW, et al. Risedronate in Paget's disease: preliminary results of a multi-center study. Semin Arthritis Rheum 1994; 23 (4): 272
11. 11. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19 (1): 80-100
12. 12. Licata AA. Bisphosphonate therapy. Am J Med Sci 1997 Jan; 313: 17-22
13. 13. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995 Oct; 10: 1478-87
14. 14. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RAS. J Bone Miner Res 1998; 13 (4): 581-9
15. 15. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999 Oct 13; 282: 1344-52
16. 16. Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85 (5): 1895-900
17. 17. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000; 11: 83-91
18. 18. Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 1998; 22 (1): 51-5
19. 19. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998 Jun; 13: 1032-8
20. 20. Brown JP, Hosking DJ, Ste-Marie L-G, et al. Risedronate, a highly effective, short-term oral treatment for Paget' s disease: a dose-response study. Calcif Tissue Int 1999; 64 (2): 93-9
21. 21. Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999 May; 106: 513-20
22. 22. Goa KL, Balfour JA. Risedronate. Drugs Aging 1998 Jul; 13: 83-91
23. 23. Eriksen EF, Brown JP, Boling E, et al. Beneficial effects of risedronate in corticosteroid-treated patients: histology and histomorphometry [abstract]. Bone 1998; 23 (5 Suppl.): S403
24. 24. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994 Jan-Feb; 15: 41-9
25. 25. Mitchell DY, Eusebio RA, Sacco-Gibson NA, et al. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 2000 Mar; 40: 258-65
26. 26. Mitchell DY, Barr WH, Eusebio RA, et al. Determination of intravenous pharmacokinetics, absolute and relative bioavailability, and intra-and intersubject variability of risedronate using a four period replicate study design [abstract no. 3444]. Pharm Res 1997; 14: S-610
27. 27. Mitchell DY, Heise MA, Pallone KA, et al. The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 1999 Oct; 48: 536-42
28. 28. Aventis Pharmaceuticals Inc. Actonel (risedronate sodium tablets) prescribing information. Kansas City (MO: Aventis Pharmaceuticals Inc, Apr 2000
29. 29. Mitchell DY, Eusebio R, Axelrod DW, et al. Risedronate pharmacokinetics following single and multiple dose intravenous administration [abstract no. P321]. Bone 1997; 20: 100S
30. 30. Mitchell DY. St Peter JV, Eusebio RA, et al. Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 2000 Mar; 49: 215-22
31. 31. Melton III LJ, Chrischilles EA, Cooper C, et al. Perspective: how many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-10
32. 32. Rubin CD. Southwestern Internal Medicine Conference: age-related osteoporosis. Am J Med Sci 1991; 301: 281-98
33. 33. Ullrich I. Osteoporosis. West Virginia Med J 1991; 87: 347-50
34. 34. Cummings S, Black D, Nevitt M, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341: 72-5
35. 35. Lindsay R, Silverman SL, Cooper C. et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285 (3): 320-3
36. 36. Adami S, Kanis JA. Assessment of involutional bone loss: methodological and conceptual problems. J Bone Miner Res 1995; 10: 511-7
37. 37. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis [online]. NOF; 2000. Available from: URL: http://www.nof.org/physguide [accessed 2001 Mar 30]
38. 38. Consensus Statements (NIH Consensus Development Program): 111. Osteoporosis prevention, diagnosis, and therapy. National Institutes of Health Consensus Development Conference Statement. March 27-29, 2000. Available from URL: http://odp.od.nih.gov/consensus/cons/111/111_statement.htm#4 [Accessed 2000 Sep 16]
39. 39. Lindsay R. Estrogen deficiency. In: Riggs BL, Melton LJ, editors. Osteoporosis: etiology, diagnosis, and management. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1995; 133-60
40. 40. Kanis JA, Melton III LJ, Christiansen C, et al. Perspective: the diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-41
41. 41. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9
42. 42. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71
43. 43. McClung MR, Bensen W, Bolognese MA, et al. Risedronate increases BMD at the hip, spine and radius in postmenopausal women with low bone mass [abstract no. P269]. J Bone Miner Res 1997 Aug; 12 Suppl. 1: S169
44. 44. Ebeling P, Roberts A, D'Emden M, et al. Risedronate prevents bone loss in early postmenopausal women [abstract no. SA377]. J Bone Miner Res 1999; 14 Suppl. 1: S403
45. 45. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344 (5): 333-40
46. 46. Hooper M, Hanley DA, Eastell R, et al. Sustained effect of risedronate in the prevention of the first vertebral fracture in women [abstract]. J Bone Miner Res 2000 Sep; 15 Suppl. 1: S428
47. 47. Brown J-P, Hosking D, Josse R, et al. Risedronate rapidly and consistently reduces risk of further vertebral fracture in women with multiple vertebral fractures [abstract]. J Bone Miner Res 2000 Sep; 15 Suppl. 1: 150
48. 48. Harris ST, Wasnich R, Ettinger M, et al. The effects of risedronate plus estrogen compared with estrogen alone in postmenopausal women [abstract]. J Bone Miner Res 1999 Sep; 14 Suppl.: 29
49. 49. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265-8
50. 50. Hamdy RC. latrogenic osteoporosis. South Med J 1999 Nov; 92: 1131-3
51. 51. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15 (6): 993-1000
52. 52. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137-95
53. 53. Curtiss Jr PH, Clark WS, Herndon CH, et al. Vertebral fractures resulting from prolonged cortisone and corticotrophin therapy. JAMA 1954; 156: 467-9
54. 54. Laan RFJM, van Riel PLCM, van de Putte LBA, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized controlled study. Ann Intern Med 1993; 119. 963-968
55. 55. Lukert BP, Raisz LG. Glucorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352-64
56. 56. Montemurro L, Fraioli P, Riboldi A, et al. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Interna 1990; 5: 164-8
57. 57. Nordborg E, Hansson T, Jonson R, et al. Bone mineral content of the third lumbar vertebra during 18 months of prednisolone treatment for giant cell arteritis. Clin Rheumatol 1993; 12: 455-60
58. 58. Als OS, Gotfredsen A, Christiansen C. The effect of glucocorticoids on bone mass in rheumatoid arthritis patients: influence of menopausal state. Arthritis Rheum 1985; 28: 369-75
59. 59. Pons F, Peris P, Guañabens N, et al. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in premenopausal women. Br J Rheumatol 1995; 34: 742-6
60. 60. Eggelmeijer F. Prevention and treatment of glucocorticoid-induced osteoporosis. Pharm World Sci 1998; 20 (5): 193-7
61. 61. Homik JE. Cranney A, Shea B, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999; 26 (5): 1148-57
62. 62. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999 Nov; 42: 2309-18
63. 63. Reid DM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15 (6): 1006-13
64. 64. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277-85
65. 65. Maricic M, Weryha G, Emkey R, et al. Risedronate increases bone mass in men receiving glucocorticoid therapy [abstract]. Arthritis Rheum 2000 Sep; 43 (9 Suppl.): S203
66. 66. Frame B, Marel GM. Paget disease: a review of current knowledge. Radiology 1981; 141: 21-4
67. 67. Wallach S. Treatment of Paget's disease. In: Advances in internal medicine. v. 27, Chicago (IL): Year Book Medical Publishers, 1982: 1-43
68. 68. Merkow RL, Lane JM. Paget's disease, part II. In: Sculco TP. editor. Orthopedic care of the geriatric patient. St Louis (MO): CV Mosby, 1985: 253-68
69. 69. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values. N Engl J Med 1992; 327 (10): 718-24
70. 70. Young DS. Implementation of SI units for clinical laboratory data. Style specifications and conversion tables. Ann Intern Med 1987; 106 (1): 114-29
71. 71. Deal C, Piette F, Olszynski W, et al. Risedronate is well-tolerated in osteoporotic patients, including those over 80 years of age. Arthritis Rheum 2000 Sep; 43 Suppl,: S203
72. 72. Eastell R, Watts N, McClung M, et al. Integrated safety analyses of risedronate in postmenopausal women [abstract]. 81st Annual Meeting, Endocrine Society 1999 Jun 12: 443
73. 73. Brown JP, Singer FR, Siris FS, et al. A safety review of the use of risedronate in the treatment of Paget's disease of bone [abstract]. J Rheumatol 1998 Jun; 25 Suppl. 52: 53
74. 74. Singer FR, Minoofar PN. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 1995; 6: 259-88
75. 75. Zysset E, Ammann P, Jenzer A, et al. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner 1992 Sep; 18 (3): 237-49
76. 76. Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987 Dec; 41 (6): 326-31
77. 77. Ward C, Sacco-Gibson N, Mitchell DY, et al. Single dose risedronate (pyridinyl-bisphosphonate) does not induce acute phase reaction in healthy subjects [abstract no. M660]. J Bone Miner Res 1996; 11 Suppl. 1: S346
78. 78. Sacco-Gibson N, Mitchell DY, Eusebio RA, et al. Risedronate (a pyridinyl bisphosphonate) does not induce acute phase reaction after single and multiple dose intravenous administration [abstract no. P329]. Bone 1997; 20: 102S
79. 79. Fogelman I, Moreland L, Woodson G, et al. Gastrointestinal side effects and endoscopic findings similar between risedronate and placebo-treated patients. Osteoporosis Int 2000; 11 Suppl. 2: S179
80. 80. Hosking D. Bockman R, Glowinski J, et al. Similar gastrointestinal side effects and endoscopic findings between risedronate and placebo-treated patients. J Bone Miner Res 2000 Sep; 15 Suppl. 1: S428
81. 81. Lanza FL, Hunt RH, Thomson ABR, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631-8
82. 82. Adachi JD, Adami S, Miller PD, et al. Risedronate is well-tolerated in alendronate-intolerant postmenopausal women [abstract]. J Bone Miner Res 2000 Sep; 15 Suppl. 1: S429
83. 83. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95: 3112-7
84. 84. Aventis Pharma Pty Ltd. Product information: Actonel® (risedronate disodium). Lane Cove, NSW: Aventis Pharma Pty Ltd, Aug 2000
85. 85. Procter and Gamble Pharmaceutical. Actonel®: risedronate sodium tablets 5 and 30 mg (as the hemi-pentahydrate). Toronto, Ontario, Canada, Jul 2000
86. 86. Hoechst Marion Roussel SA. Package insert leaflet: Actonel® 30 mg. Maroussi, Greece, Dec 2000
87. 87. Aventis Pharmaceuticals. Actonel 30 mg film-coated tablets. Costa Rica, Oct 1999
88. 88. Cranney A, Welch V, Tugwell P, et al. Responsiveness of end-points in osteoporosis clinical trials - an update. J Rheumatol 1999; 26 (1): 222-8
89. 89. Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151: 2026-32
90. 90. Adis meeting report: osteoporosis becoming a disease of the past? Drugs RD 1999 Mar; 1: 231-2
91. 91. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338 (11): 736-46
92. 92. Francis RM. Management of established osteoporosis. Br J Clin Pharmacol 1998; 45 (2): 95-9
93. 93. Barman Balfour JA, Goa KL. Intranasal salcatonin (salmon calcitonin): an updated review of its pharmacological properties and therapeutic use in the management of postmenopausal osteoporosis. Drugs Aging (In press)
94. 94. Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998 Oct; 244: 271-92
95. 95. Torgerson DJ, Reid DM. The economics of osteoporosis and its prevention: a review. Pharmacoeconomics 1997 Feb; 11: 126-38
96. 96. Roux C, Dougados M. Treatment of patients with Paget's disease of bone. Drugs 1999 Nov; 58: 823-30